Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008.

"Dirucotide has demonstrated the ability to safely affect MS progression in previous studies and we look forward to the results of the Canadian/European trial (MAESTRO-01) in the second half of this year," said Kevin Giese, President and CEO of BioMS Medical. "Our hope is that the results of this trial will confirm that dirucotide is able to significantly slow the progression of MS, specifically in patients with secondary progressive multiple sclerosis."

Currently, BioMS is conducting two clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

        -  MAESTRO-01: On January 22, 2007, BioMS announced that this pivotal
           phase III trial, being conducted in Canada and Western Europe, had
           completed full recruitment of 611 SPMS patients at 47 trial sites
           in ten countries. To date, there have been nine positive safety
           reviews from the Data Safety Monitoring Board (DSMB). The primary
           clinical endpoint for MAESTRO-01 (and MAESTRO-03) is defined as a
           statistically and clinically significant increase in the time to
           progression of the disease as measured by the Expanded Disability
           Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4
           immune response genes.

           On August 13, 2008, the DSMB conducted a scheduled interim
           analysis of efficacy and safety and recommended that the trial
           continue to completion. The interim analysis evaluated the first
           200 patients to complete MAESTRO-01 and assessed the likelihood of
           the study reaching
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... 2014 The Asian arthroscopic devices report ... analysis and forecast of revenue. The arthroscopic devices market ... by 2018, at a CAGR of 6.5% from 2013 ... Asian arthroscopic devices market, to get an idea of ... of the segmentation of arthroscopic devices market in the ...
(Date:10/18/2014)... October 18, 2014 The Asia-Pacific Liquid ... segments the concerned market in Asia-Pacific with analysis and ... million in 2013, and is expected to reach $380.0 ... 2013 to 2018. , Browse through the TOC of ... idea of the in-depth analysis provided. This also provides ...
(Date:10/18/2014)... October 18, 2014 The Biomass ... in the five years to 2014. The industry's expansion ... energy tax credits that encouraged the use of biomass ... portfolio standards (RPSs), which require local utilities to generate ... total energy portfolio. Increased campaigning for green technology also ...
(Date:10/18/2014)... The report " Cloud Analytics Market ... Speech; Machine; Video; Predictive Analytics: Global Advancements, Delivery ... Analysis (2013 - 2018) ", defines and segments ... segments with an in-depth analysis and forecasting of ... driving this market, various restraints, and opportunities impacting ...
Breaking Biology Technology:The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 3Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 2Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 2Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 4Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 5
... it doesn,t just go to his or her head: It ... biomolecules that may serve as a permanent record of each ... Act grant from the National Institute of Drug Abuse (NIDA) ... physicist John Wikswo will attempt to determine whether an individual,s ...
... - Oncothyreon Inc. (NASDAQ: ONTY ) today reported financial ... 2009 and provided a product pipeline update. Management will hold ... PT (see below for details). , Oncothyreon reported a loss ... September 30, 2009, compared with a loss from operations of ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: ... and advances a diverse portfolio of promising cancer-related products ... financial results for the first quarter of fiscal 2010, ... quarter, we continued to advance our lead drug nimotuzumab, ...
Cached Biology Technology:Interdisciplinary research team developing novel drug detection technology 2Interdisciplinary research team developing novel drug detection technology 3Interdisciplinary research team developing novel drug detection technology 4Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 2Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 3Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 4Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 5Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 6Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 7Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 8YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 2YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 3YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 4YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 5YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 6YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 7YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 8YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 9YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 10YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 11YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 12
(Date:10/14/2014)... 14, 2014 – High doses of fish oil supplements, rich ... common type of irregular heartbeat in which the heart can ... of the AFFORD trial led by the Montreal Heart Institute ... of Cardiology on October 7th. , For the trial, ... were randomly assigned to 4 grams of fish oil a ...
(Date:10/14/2014)... international team of researchers, led by the Chinese Academy ... Nature Genetics a brief genomic history of ... the tomato plant. , The C.M. Rick Tomato Genetics ... in this study by providing seed of both cultivated ... which builds on the first tomato genome sequence completed ...
(Date:10/14/2014)... 2014 – Researchers from Stanford University School of Medicine ... by cells and the activation of muscle stem cells. ... generate energy during times of nutrient deprivation. The scientists ... this protective mechanism is operational it also seems to ... reveals that when stem cells emerge from a quiescent ...
Breaking Biology News(10 mins):Autophagy helps fast track stem cell activation 2
... MD (July 27, 2010) -- Fluids experts writing in ... published by the American Institute of Physics, are projecting ... probe the properties of turbulence near walls. High-Reynolds-number flows ... aeronautics, naval applications, energy conversion processes, manufacturing, mixing and ...
... be difficult for scientists to see the deforestation for the ... of the Brown-MBL Graduate Program in Biological and Environmental Sciences ... and her colleagues, who take a big-picture approach to greenhouse ... Proceedings of the National Academy of Sciences , the team ...
... release is available in Spanish . ... for deciphering the genetics of a native prairie grass being ... genetic map of switchgrass, published by Christian Tobias, a molecular ... Calif., and his colleagues, is expected to speed up the ...
Cached Biology News:A future with or without trees 2A new tool for improving switchgrass 2
A collection of 42 spots with normal tissues from different organs of C57 mice, rat and human....
... The V-106 voice-coil scanning and positioning ... small samples have to be positioned ... high resolution. It provides superior responsiveness ... drives. The mechanics (X or XY ...
Improves spot morphology and DNA binding to the slide resulting in increased hybridization signal. ID Clarifier: Optimized spotting solution for use with SigmaScreen APS Coated Slides for Microarrays...
... General description: Humidity wells in the base ... chamber humidity and probe hydration around the ... eliminates the risk of waterbath contamination. This ... temperature waterbaths or hybridisation ovens. Linkage: This ...
Biology Products: